期刊文献+

非小细胞肺癌中肝细胞生长因子受体蛋白表达及其与肿瘤细胞增殖、血管生成的关系 被引量:5

Expression of c-Met Protein in Non-small Cell Lung Carcinoma and Its Relationship with Tumor Cell Proliferation and Angiogenesis
下载PDF
导出
摘要 目的:检测肝细胞生长因子受体(cMet)在非小细胞肺癌(NSCLC)中的表达,探讨其与肿瘤细胞增殖和血管形成的关系。方法:运用免疫组织化学SP法对14例正常肺组织和45例NSCLC组织中的cMet、核增殖相关抗原Ki67进行检测。用CD34单克隆抗体检测微血管密度(MVD)。结果:正常肺组织cMet表达率为21.4%(3/14),而在NSCLC中为60.0%(27/45),其在肿瘤和正常组织中的表达差异有显著性(P<0.05)。cMet的表达与组织学类型、分化程度和淋巴结转移有关(P<0.05),与年龄、性别和临床分期均无关。cMet阳性表达组的Ki67指数和MVD明显高于cMet表达阴性组(P<0.01,P<0.05),cMet的表达与Ki67指数和MVD有关。结论:cMet的表达与NSCLC的增殖和血管形成密切相关,可作为诊断和判断预后的一个指标。 Objective: To investigate the expression of hepatocyte growth factor receptor(c-Met) in non-small cell lung carcinoma(NSCLC), and to explore its relationship with tumor cell proliferation and angiogenesis. Methods: Immunnohistochemistry (SP method) was adopted to detect c-Met and ki-67 proteins expression in 14 cases of normal pulmonary tissue(NPT) and 45 cases of NSCLC. Microvessel density (MVD) was determined by anti-CD34 immunostaining. Results: In NPT, positive rate of c-Met was 21.4%(3/14), but in all of NSCLC was 60.0%(27/45). The difference of c-Met expression was significant between NSCLC and NPT(P<0.05). c-Met expression was related to differentiation degree histotype and lymph node metastasis,but not to age, sex and clinic stage.The Ki-67 indexes and MVD were significantly higher in c-Met positive tumors than those in the negative ones(P<0.01,P<0.05). The expression of c-Met was also correlated with Ki-67 indexes and MVD. Conclusion: The expression of c-Met has strong relationship with tumor cell proliferation and angiogenesis. It could serve as a diagnosable and prognostic factor of NSCLC.
出处 《武汉大学学报(医学版)》 CAS 2005年第3期273-275,283,i004,共5页 Medical Journal of Wuhan University
基金 国家自然科学基金项目(编号:39870305)
关键词 肺肿瘤 c—Met原癌基因蛋白 增殖 血管生成 免疫组织化学 Lung Neoplasm c-Met Oncoprotein Proliferation Angiogenesis Immunnohistochemistry
  • 相关文献

参考文献9

  • 1Maulik G, Shrikhande A, Kijima T, et al. Role of the hepatocyte growth factor receptor, c-MET, in oncogenesis and potential for therapeutic inhibition.Cytokine-Growth Factor Rev,2002,13(1):41.
  • 2Ma PC, Maulik G, Christensen J, et al. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev,2003,22(4):309.
  • 3Edakuni G, Sasatomi E, Satoh T, et al. Expression of the hepatocyte growth factor/c-Met pathway is increase at the cancer front in breast carcinoma. Pathol Int,2001,51(3):172.
  • 4Tsao MS, Liu N, Chen JR, et al. Differetial expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancer. Lung Cancer,1998,20(1):1.
  • 5Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown.J Cell Physiol, 2000, 182(3):311.
  • 6Tacchini L, De Ponti C, Matteucci E, et al. Hepatocyte growth factor-activated NF-kappaB regulates HIF-1 activity and ODC expression, implicated in survival, differently in different carcinoma cell lines. Carcinogenesis,2004,25(11):2 089.
  • 7Paumelle R, Tulasne D, Kherrouche Z, et al. Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway. Oncogene, 2002,21(15): 2 309.
  • 8Recio JA, Merlino G. Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1.Oncogene,2002, 21(7):1 000.
  • 9Ishizawa K, Kubo H, Yamada M, et al. Hepatocyte growth factor induces angiogenesis in injured lungs through mobilizing endothelial progenitor cells.Biochem Biophys Res Commun,2004, 324(1):276.

同被引文献36

  • 1王伟,杨连粤,杨治力,黄耿文,鲁伟群.自分泌运动因子受体和RhoC基因在肝细胞癌侵袭转移中的作用[J].中华肝胆外科杂志,2004,10(6):408-410. 被引量:4
  • 2王萌,陈公琰,蔺铁.survivin、VEGF在非小细胞肺癌中的表达及相关性研究[J].肿瘤防治研究,2006,33(1):5-7. 被引量:17
  • 3彭亦良,梁后杰.癌细胞运动与迁移的分子机制[J].中国生物化学与分子生物学报,2006,22(10):794-798. 被引量:19
  • 4Jumper C, Cobos E, Lox C. Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metallopruteinase-1 ( TIMP-1 ) in patients with either advanced small-cell lung eancer or non-small-cell lung cancer prior to treatment [ J ]. Respir Med, 2004,98 (2) : 173 - 177.
  • 5Suzuki M, Iizasa T, Fujisawa T, et al. Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in nonsmall-cell lung cancer[ J ]. Invasion Metastasis, 1998 -1999,18 (3) : 134 - 141.
  • 6Nuttall R K, Pennington C J, Taplin J, et al. Elevated membrane-type matrix metalloproteinases in gliomas revealed by profiling proteases and inhibitors in human cancer cells [ J ]. Mol Cancer Res, 2003,1 (5) : 333 - 345.
  • 7Jumper C,Cobos E,Lox C.Determination of the serum matrix metalloproteirase-9(MMP-9) and tissue inhibitor of matrix metalloproteinase-1(TIMP-1) in patients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatment[J].Respir Med,2004,98(2):173-177.
  • 8Suzuki M,Izasa T,Fujisawa T,et al.Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in non-small lung cancer[J].Invasion Metastasis,1998-1999,18(3):134-141.
  • 9Nuttall R K,Pennington C J,Taplin J,et al.Elevated membranetype matrix metalloproteinases in gliomas revealed by profiling proteasea and inhibitor in human cancer cell[J].Mol Cancer Res,2003,1(5):333-345.
  • 10Maulik G, Shrikhande A, Kijima T, et al. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and poten tial for therapeutic inhibition [J]. Cytokine Growth Factor Rev, 2002,13(1) :41-59.

引证文献5

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部